New call-to-action
New call-to-action
New call-to-action

Foundation for Prader-Willi Blog | News

Categories

FDA Grants Rare Pediatric Disease Designation to CSTI-500

The FDA has granted Rare Pediatric Disease Designation (RPDD) to ConSynance Therapeutics' new investigational drug, CSTI-500 for the treatment of Prader-Willi Syndrome in children and adolescents. This special status is granted to drugs and biologics...
July 26, 2024 Read More

Topics: News

FPWR Joins the Rare Disease Diversity Coalition

Improving diversity, equity, inclusion, and accessibility (DEIA) in PWS clinical research is a priority for FPWR, and we are working to partner with experts and other patient groups working in this area. FPWR has recently joined the Rare Disease Dive...
July 2, 2024 Read More

Topics: News

Recent Advances in Drug Development Bring Treatments Within Reach for PWS

Exciting developments are sweeping through the PWS community, spotlighting two potential treatments: Soleno’s DCCR and Aardvark’s ARD-101. Recognition of the PWS community's involvement must be given, as hundreds of volunteers have participated in PW...
May 21, 2024 Read More

Topics: News

Advancing Prader-Willi Syndrome Care With the New PWS Profile Tool

PWS impacts many aspects of our children’s lives. The hallmark struggle for those affected by PWS is hyperphagia, or excessive appetite. But beyond hyperphagia, individuals with PWS are susceptible to other behavioral and emotional problems that affe...
May 13, 2024 Read More

Topics: News, Resource Development, Research, PWS People

May is #PWSAwareness Month | We Have Your PWS Awareness Resources

May is PWS Awareness Month. A time to raise awareness and advance research so we may find new treatments for Prader-Willi syndrome (PWS). By coming together this month, we can amplify our impact and propel treatments for PWS forward faster. Since 201...
April 24, 2024 Read More

Topics: News

Top 10 Reasons to Attend the 2024 FPWR Family Conference

Join us September 27–28 for our annual gathering of movers, shakers, thinkers, and doers at this year’s FPWR Family Conference! It's a unique opportunity to connect, learn, and grow alongside like-minded individuals who are dedicated to making a diff...
March 20, 2024 Read More

Topics: News

Analysis of Hyperphagia Questionnaire for Clinical Trials (HQ-CT) Scores

The Hyperphagia Questionnaire for Clinical Trials (HQ-CT) is typically completed by caregivers for individuals with PWS who are enrolled in clinical trials. The questionnaire is designed to evaluate changes inhyperphagia during the course of the tria...
January 10, 2024 Read More

Topics: News, Research, Parents

Improving the PWS Clinical Trial Experience for Families and Clinical Study Site Staff

It has been an exciting time for PWS research and clinical trials. The field has been working hard to find effective treatments for the symptoms of PWS to help our children lead more independent and fulfilling lives. In the last several years, there ...
November 29, 2023 Read More

Topics: News, Clinical Issues, Resource Development

Recordings from FPWR’s Annual Family Conference: What’s Next for DCCR?

Soleno Therapeutics recently shared data from their DESTINY PWS study, an international, placebo-controlled Phase 3 study of DCCR (Diazoxide Choline Controlled-Release) drug trial. To further establish the effects of DCCR administration on hyperphagi...
October 25, 2023 Read More

Topics: News, Hunger Satiety, Research

About FPWR

The Foundation for Prader-Willi Research (federal tax id 31-1763110) is a nonprofit corporation with federal tax exempt status as a public charity under section 501(c)(3).

4star120x60

NORD_MembershipLogo_Platinum_2021

excellence-in-giving-logo

Main Menu

Our Mission

The mission of FPWR is to eliminate the challenges of Prader-Willi syndrome through the advancement of research and therapeutic development.

Contact Us

Foundation for Prader-Willi Research
Phone: 888-322-5487
Email: info@fpwr.org

FPWR
440 N Barranca Ave #3620
Covina, CA 91723

Copyright © 2020. All Rights Reserved. Terms of Use. Privacy Policy. Copyright Infringement Policy. Disclosure Statement.